secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zoetis Inc. (ZTS)
CIK:        0001555280
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001555280-25-000272
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zoetis Q3 adjusted EPS $1.70 (+8%); revenue $2.4B (+4% organic); FY guidance narrowed
--------------------------------------------------------------------------------

- Q3 revenue $2.4B (+1% reported; +4% organic operational); net income $721M, $1.63 diluted EPS (+9% YoY).
- Adjusted net income $754M, $1.70 adjusted diluted EPS (+8% reported; +12% organic operational).
- U.S. segment revenue $1.3B (-2% reported, +3% organic); International $1.1B (+3% reported, +6% organic).
- Updated FY2025 revenue guidance $9.400-9.475B (5.5-6.5% organic growth); adjusted EPS $6.30-6.40 maintained.
- Regulatory milestones: Lenivia approved in Canada/EU for canine OA pain; Portela approved in EU for feline OA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1555280/000155528025000272/0001555280-25-000272-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1555280/000155528025000272/zts-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001555280-25-000272

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer